Adalimumab + Risankizumab

Phase 3Recruiting

0 views this week 0 watching⚡ Active

Interest: 47/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Juvenile Psoriatic Arthritis

Conditions

Juvenile Psoriatic Arthritis

Trial Timeline

Jul 8, 2024 → Oct 1, 2028

NCT ID

NCT06100744

About Adalimumab + Risankizumab

Adalimumab + Risankizumab is a phase 3 stage product being developed by AbbVie for Juvenile Psoriatic Arthritis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06100744. Target conditions include Juvenile Psoriatic Arthritis.

What happened to similar drugs?

7 of 20 similar drugs in Juvenile Psoriatic Arthritis were approved

Approved (7) Terminated (1) Active (13)

✅Tocilizumab + NSAIDs + CSs + MTXRocheApproved

✅TocilizumabRocheApproved

✅VIMOVO 250/20 + VIMOVO 375/20 + VIMOVO 500/20AmgenApproved

✅800 mg ibuprofen/26.6 mg famotidineAmgenApproved

✅methotrexate + methotrexate - etanercept - prednisolone armAmgenApproved

✅SulfasalazinePfizerApproved

✅Celecoxib + NaproxenPfizerApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06100744	Phase 3	Recruiting	Jul 8, 2024	Oct 1, 2028	Juvenile Psoriatic Arthritis

Competing Products

20 competing products in Juvenile Psoriatic Arthritis

See all competitors

Product	Company	Stage	Hype Score
PLX-200 + Placebo	Polaryx Therapeutics	Phase 3	37
MRA(Tocilizumab)	Chugai Pharmaceutical	Phase 3	40
MRA(Tocilizumab) + placebo	Chugai Pharmaceutical	Phase 3	40
MRA(Tocilizumab)	Chugai Pharmaceutical	Phase 3	40
MRA(Tocilizumab)	Chugai Pharmaceutical	Phase 3	40
Adalimumab	Eisai	Phase 3	40
Abatacept	Ono Pharmaceutical	Phase 3	40
Ixekizumab + Adalimumab	Eli Lilly	Phase 3	44
Baricitinib + Placebo	Eli Lilly	Phase 3	40
Baricitinib	Eli Lilly	Phase 3	47
Baricitinib + Tocilizumab	Eli Lilly	Phase 3	47
adalimumab + Methotrexate	AbbVie	Pre-clinical	26
Upadacitinib	AbbVie	Phase 1	33
Upadacitinib + Tocilizumab	AbbVie	Phase 3	47
Adalimumab	AbbVie	Phase 3	40
naproxen + esomeprazole	AstraZeneca	Phase 1	29
Alendronate (Fosamax)	Merck	Pre-clinical	26
canakinumab	Novartis	Phase 3	40
Secukinumab	Novartis	Phase 1	36
ACZ885 150 mg (Canakinumab)	Novartis	Phase 3	40